E-Synergy
VC Fund
Los Angeles, United States
E-Synergy is a VC fund in Los Angeles focused on Software and Computer. E-Synergy was founded in 1999 by four technology entrepreneurs as an independent venture capital firm focusing on early stage investments. They believe that to be successful in early stage technology companies in particular, investors must bring more than just capital to the table. The founding directors have over 50 years experience themselves asCEOs of technology development and licensing companies. This considerable expertise combined with the financial and VC experience of the E-Synergy investment team enables them to take a hands on approach to investing and leverage real value from the capital they provide.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries E-Synergy invests in
Stages E-Synergy invests in
Countries E-Synergy invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Investment Focus
Industry
- Software 2 (33%)
- Computer 1 (17%)
- Electronics 1 (17%)
- Biotechnology 1 (17%)
- Manufacturing 1 (17%)
Stage
- Funding Round 2 (33%)
- Seed 1 (17%)
- Series B 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Elaine Smyth
Investment Manager
|
Investment Manager | Total investments: 0 | Find email | |
Jonathan Gold
Director
|
Director | Total investments: 0 | Find email | |
Kathleen Garrett
Programme manager
|
Programme manager | Total investments: 0 | Find email | |
Michael Dickens
Team Member
|
Team Member | Total investments: 10 | Find email | |
Nikita Bazko
Team Member
|
Team Member | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PathXL, a Northern Ireland-based leader in digital pathology image analysis, workflow software and educational tools. PathXL’s image analysis and tissue pathology software will complement Philips’ Digital Pathology Solutions offering, and help expand the business’ leadership in this fast-growing field.Pathology involves the examination ofpatient tissue samples and plays a crucial role in the diagnosis and treatment of a wide variety of diseases, including cancer. | $201K / Dec 19, 2012 | ||
| Performa Sports is a powerful easy to use real-time sports performance analysis iPad application and online platform designed for analysts, coaches, and players to analyse and improve team and individual performances. | $172K / Seed / Jul 17, 2012 | ||
| Ateeda Limited provides EDA tools for analog test of ADCs and DACs, regulators, references, and drivers for mixed signal semiconductor and electronics manufacturing industries. It offers pushbutton built in self test for linear circuits and digital testing of analog circuits. The company was incorporated in 2005 and is based in Edinburgh, theUnited Kingdom. | $655K / Jun 30, 2010 | ||
| R2C Online provides a community data network for the management and communication of commercial vehicle inspection and maintenance records. | $985K / Seed / Jan 17, 2008 | ||
| Critical Pharmaceuticals is a biotechnology company with proprietary drug delivery technologies for the sustained release and nasal delivery of proteins and peptides and labile or insoluble small molecules. Critical Pharmaceuticals was founded by Professor Steve Howdle in 2002 based on his research into supercritical fluids. When gases reach acertain temperature and pressure (the critical point) they become "supercritical" and take on both gas and liquid like properties. He noticed that supercritical carbon dioxide (scCO2) was able to penetrate certain polymers, and in a moment of inspiration realised that this could be used to mix thermally labile or solvent sensitive substances into the polymers. | $786K / Series B / Feb 23, 2007 | ||
| PathXL, a Northern Ireland-based leader in digital pathology image analysis, workflow software and educational tools. PathXL’s image analysis and tissue pathology software will complement Philips’ Digital Pathology Solutions offering, and help expand the business’ leadership in this fast-growing field.Pathology involves the examination ofpatient tissue samples and plays a crucial role in the diagnosis and treatment of a wide variety of diseases, including cancer. |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does E-Synergy invest in?
E-Synergy invests primarily in Software, Computer and Electronics startups, most often at Funding Round and Seed stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact E-Synergy?
Public channels for E-Synergy include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at E-Synergy?
The team at E-Synergy includes Elaine Smyth (Investment Manager), Jonathan Gold (Director) and Kathleen Garrett (Programme manager), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
